Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow. In this report, we show that elevation of angiopoietin-1 in myelodysplastic CD34+ stem-like cells is associated with higher...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Bachegowda, Lohith, Morrone, Kerry, Winski, Shannon L., Mantzaris, Ioannis, Bartenstein, Matthias, Ramachandra, Nandini, Giricz, Orsi, Sukrithan, Vineeth, Nwankwo, George, Shahnaz, Samira, Bhagat, Tushar, Bhattacharyya, Sanchari, Assal, Amer, Shastri, Aditi, Gordon-Mitchell, Shanisha, Pellagatti, Andrea, Boultwood, Jacqueline, Schinke, Carolina, Yu, Yiting, Guha, Chandan, Rizzi, James, Garrus, Jennifer, Brown, Suzy, Wollenberg, Lance, Hogeland, Grant, Wright, Dale, Munson, Mark, Rodriguez, Mareli, Gross, Stefan, Chantry, David, Zou, Yiyu, Platanias, Leonidas, Burgess, Laurence E., Pradhan, Kith, Steidl, Ulrich, Verma, Amit
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5398415/
https://ncbi.nlm.nih.gov/pubmed/27287719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3062
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak